Lunai Bioworks Announces Receipt of Nasdaq Determination and Intention to Voluntarily Delist and DeregisterPRNewsWire · 2 days ago
Lunai Bioworks (NASDAQ: LNAI) Expands Parkinson's Platform Through Exclusive Tanaist AgreementPRNewsWire · Sep 22, 2026
Lunai Bioworks (Nasdaq: LNAI) Demonstrates AI Chemical-Risk Screening for Generative AIPRNewsWire · Sep 16, 2026
Lunai Bioworks (NASDAQ: LNAI) Issues Correction to Press Release Regarding Second Amended ComplaintPRNewsWire · Sep 4, 2026
Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling SuitPRNewsWire · Aug 27, 2026
Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027PRNewsWire · Aug 4, 2026Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."